What is Barclays's price target for PRLD?

Barclays's latest stated price target for Prelude Therapeutics Incorporated (PRLD) is $3, from its action on Jun 20, 2024.

What is Barclays's rating on PRLD?

Barclays rates PRLD Underweight, a bearish rating, as of Jun 20, 2024.

When did Barclays last change its view on PRLD?

On Jun 20, 2024, Barclays downgrades to Underweight from Equal Weight, price target $3.

Analyst firms · Barclays · PRLD

Barclays PRLD price target and rating history

Prelude Therapeutics Incorporated (PRLD) · Health Care

Barclays rates Prelude Therapeutics Incorporated (PRLD) Underweight with a $3 price target, as of its latest action on Jun 20, 2024. It has published 4 rating actions on PRLD since October 2021, including 0 upgrades and 2 downgrades.

Current rating: Underweight
Price target: $3
Median target, all firms: Too few
Actions on PRLD: 4

Barclays price target on PRLD

Barclays price target on PRLD, each point a stated target, October 2021 to June 2024.

Every Barclays rating on PRLD

Jun 20, 2024
DowngradeBarclays downgrades to Underweight from Equal Weight, price target $3
Feb 28, 2022
DowngradeBarclays downgrades to Equal-Weight from Overweight, price target $20 to $12
Nov 17, 2021
ReiterateBarclays cuts its price target to $20 from $33, keeps Overweight
Oct 8, 2021
ReiterateBarclays cuts its price target to $33 from $80, keeps Overweight

Questions about Barclays and PRLD

What is Barclays's price target for PRLD?: Barclays's latest stated price target for Prelude Therapeutics Incorporated (PRLD) is $3, from its action on Jun 20, 2024.
What is Barclays's rating on PRLD?: Barclays rates PRLD Underweight, a bearish rating, as of Jun 20, 2024.
When did Barclays last change its view on PRLD?: On Jun 20, 2024, Barclays downgrades to Underweight from Equal Weight, price target $3.

More PRLD rating histories

All Barclays ratings PRLD news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.